Oligonucleotide– tag –
-
LNP-Delivered Gene Editing Platform Targets Hepatic Lipid Metabolic Disorders for Durable, Single-Intervention Correction
Ace Therapeutics USA Overview This platform focuses on lipid nanoparticle (LNP)-delivered gene editing for heritable lipid disorders, aiming for durable, single-intervention correction of disease-driving genes in the liver. It integrates... -
RNA Therapeutics Advance with Delivery Challenges: mRNA Vaccines, siRNAs, and ASOs Drive Disease Treatment
Facebook (Ambry Genetics) USA Overview Recent publications highlight the profound impact of RNA-based therapeutic modalities, including mRNA vaccines, siRNAs, and ASOs, in treating viral infections, genetic disorders, and cancer. However... -
Micron Biomedical Secures Microneedle Contract, AbbVie’s Maviret Gains EU Approval, and Moderna’s mRNA Pipeline Advances: Diverse Drug Delivery and Discovery Progress
Drug Discovery News USA Overview The drug discovery and delivery landscape sees diverse advancements: Micron Biomedical secured a $4.5 million NIAID contract for a microneedle patch for radiation injury, highlighting advancements in pain... -
Machine Learning Accelerates Lipid Nanoparticle Design, Streamlining RNA Therapeutic Formulation Development for High Efficacy and Reduced Experimental Burden
Pharmatica USA Overview Machine learning (ML) is being applied to lipid nanoparticle (LNP) design to accelerate formulation development, improve delivery performance, and reduce experimental burden for RNA therapeutics, gene-editing syst... -
Comprehensive Guide to Lipid Nanoparticles (LNPs): Key to mRNA Vaccine Success and Future RNA Therapeutic Delivery
Inside Therapeutics USA Overview Lipid nanoparticles (LNPs) are crucial nanodrug delivery systems for nucleic acids like mRNA and siRNA, vital for mRNA vaccine success and RNA therapeutics. This guide details LNP composition (ionizable l... -
MDPI Accelerates Non-Coding RNA Cancer Therapy with Organ-Selective LNPs: Achieving Precise Delivery to Liver, Spleen, and Lung
MDPI Switzerland Overview Non-coding RNA (ncRNA) therapeutics in cancer are advancing, with their efficacy significantly influenced by lipid nanoparticle (LNP) characteristics like lipid composition, particle size, and surface charge. Re... -
Swiss Bachem Invests Over $431M in 2026 to Meet Surging Global Peptide and Oligonucleotide Demand with New Facility
Pharma Manufacturing Switzerland Overview Bachem, a Swiss CDMO specializing in peptides and oligonucleotides, is undertaking a major manufacturing capacity expansion across its global network, investing between $431 million and $493 mill... -
Backbone-Ionized Polymer iPβAE Quantitatively Guides Extra-Hepatic mRNA Expression to Spleen and Lung
Journal of the American Chemical Society USA Overview A study published in the Journal of the American Chemical Society introduces a backbone-ionized polymer (iPβAE) platform engineered for quantitatively guided extra-hepatic mRNA target... -
Asia-Pacific Revolutionizes Pharma Manufacturing: Surging Capabilities in HPAPIs, Biologics, and Advanced Therapies
BioProcess International Asia-Pacific Overview The Asia-Pacific (APAC) region is rapidly expanding its specialized pharmaceutical manufacturing capabilities beyond traditional APIs, focusing on high-value modalities like HPAPIs, ADCs, mR... -
Mannosylated Spleen-Targeted LNP (LNP-PAM) Enhances mRNA Delivery to Antigen-Presenting Cells, Overcoming Liver Tropism
ACS Publications USA Overview A novel mannosylated spleen-targeted lipid nanoparticle (LNP-PAM) has been developed to significantly enhance mRNA delivery to antigen-presenting cells by integrating active and endogenous targeting. This sy...
